Generalized Myasthenia Clinical Trials

1 recruiting

Frequently Asked Questions

Common questions about Generalized Myasthenia clinical trials

A clinical trial is a carefully designed research study that tests new medical treatments, drugs, devices, or approaches in human volunteers. Every approved medication and treatment available today was proven safe and effective through clinical trials.

All clinical trials are reviewed and approved by Institutional Review Boards (IRBs) — independent committees that evaluate patient safety. Trials follow strict protocols, and your health is monitored closely throughout. You can withdraw at any time.

Not necessarily. Many trials compare the new treatment against the current standard of care, meaning all participants receive active treatment. When placebos are used, they are typically combined with standard treatment, not given alone. The trial description will always specify the design.

Under the Affordable Care Act, most private insurers are required to cover routine patient care costs during a clinical trial. The sponsor typically covers the investigational treatment itself. Medicare also covers routine costs for qualifying trials.

Yes. Participation is completely voluntary. You can withdraw at any time, for any reason, without it affecting your access to standard medical care.

Each trial has specific eligibility criteria — including age, diagnosis, disease stage, prior treatments, and general health. Browse the trials listed above and check their eligibility sections. You can also contact the trial site directly to discuss your situation.

Showing 120 of 26 trials

Recruiting
Phase 3

PK, PD, Safety, and Efficacy Study of Gefurulimab in Pediatric Patients With AChR+ Generalized Myasthenia Gravis

Generalized Myasthenia GravisgMG
Alexion Pharmaceuticals, Inc.12 enrolled13 locationsNCT06607627
Recruiting
Phase 2Phase 3

A Study to Evaluate Subcutaneous Zilucoplan in Pediatric Participants With Generalized Myasthenia Gravis

Generalized Myasthenia Gravis
UCB Biopharma SRL8 enrolled9 locationsNCT06055959
Recruiting
Phase 3

A Study to Investigate the Efficacy, Safety and Tolerability of Remibrutinib Versus Placebo in Adult Patients With Generalized Myasthenia Gravis

Generalized Myasthenia Gravis
Novartis Pharmaceuticals180 enrolled93 locationsNCT06744920
Recruiting
Phase 3

A Phase III Study to Investigate Efficacy, Safety and Tolerability of Iptacopan Compared With Placebo in Participants Aged 18 to 85 Years With gMG.

Generalized Myasthenia Gravis
Novartis Pharmaceuticals146 enrolled110 locationsNCT06517758
Recruiting
Phase 2Phase 3

A Study of Rozanolixizumab in Pediatric Study Participants With Moderate to Severe Generalized Myasthenia Gravis

Generalized Myasthenia Gravis
UCB Biopharma SRL12 enrolled13 locationsNCT06149559
Recruiting
Phase 3

Efficacy and Safety of a New Formulation of Oral Cladribine Compared With Placebo in Participants With Generalized Myasthenia Gravis (MyClad)

Generalized Myasthenia Gravis
Merck Healthcare KGaA, Darmstadt, Germany, an affiliate of Merck KGaA, Darmstadt, Germany264 enrolled132 locationsNCT06463587
Recruiting
Phase 2

A Study to Evaluate the Pharmacokinetics, Pharmacodynamics, Safety and Tolerability of Inebilizumab in Children With Generalized Myasthenia Gravis (gMG)

Generalized Myasthenia Gravis
Amgen15 enrolled1 locationNCT06987539
Recruiting

Epidemiological Study of Treatment Approaches in AChR-Antibody Positive Generalized Myasthenia Gravis in Russia

Rare DiseasesGeneralized Myasthenia Gravis (gMG)
AstraZeneca450 enrolled3 locationsNCT07247279
Recruiting
Phase 4

A Study to Evaluate the Clinical Outcomes of Efgartigimod PH20 SC in Adults With New-onset Generalized Myasthenia Gravis (gMG)

New Onset Generalized Myasthenia Gravis (gMG)
argenx30 enrolled18 locationsNCT06909214
Recruiting
Phase 3

A Study of Telitacicept for the Treatment of Generalized Myasthenia Gravis (UPSTREAM MG)

Generalized Myasthenia Gravis
Vor Biopharma180 enrolled84 locationsNCT06456580
Recruiting
Phase 3

Study to Assess the Efficacy and Safety of IMVT-1402 in Participants With Mild to Severe Generalized Myasthenia Gravis

Generalized Myasthenia Gravis
Immunovant Sciences GmbH231 enrolled75 locationsNCT07039916
Recruiting
Phase 3

Zilucoplan for Severe gMG Exacerbations

Generalized Myasthenia Gravis (gMG)
Miriam Freimer15 enrolled1 locationNCT07215949
Recruiting

ADAPT Forward - Master Protocol of a Platform Study to Evaluate the Safety and Efficacy of Multiple Regimens in Participants With Myasthenia Gravis

Myasthenia GravisGeneralized Myasthenia Gravis (gMG)Generalized Myasthenia Gravis+3 more
argenx70 enrolled5 locationsNCT07294170
Recruiting

Registry of Participants With Generalized Myasthenia Gravis Treated With Alexion C5 Inhibition Therapies (C5ITs)

Generalized Myasthenia Gravis
Alexion Pharmaceuticals, Inc.500 enrolled51 locationsNCT04202341
Recruiting
Phase 2Phase 3

Evaluating the Pharmacokinetics, Pharmacodynamics, and Safety of Efgartigimod Administered Intravenously in Children With Generalized Myasthenia Gravis

Generalized Myasthenia Gravis
argenx12 enrolled25 locationsNCT04833894
Recruiting
Phase 2

ADAPT Forward 1 - ISA1 - a Study to Evaluate Empasiprubart IV as add-on Therapy to Efgartigimod IV in Participants With AChR-Ab Seropositive Generalized Myasthenia Gravis With a Partial Clinical Response to Efgartigimod

Myasthenia GravisGeneralized Myasthenia Gravis (gMG)Generalized Myasthenia Gravis+3 more
argenx70 enrolled5 locationsNCT07284420
Recruiting

Early Ravulizumab Treatment Of Anti- AChR Antibody-Positive Generalized Myasthenia Gravis

Generalized Myasthenia GravisAnti-AChR Antibody Positive
Alexion Pharmaceuticals, Inc.40 enrolled23 locationsNCT06967480
Recruiting
Phase 1Phase 2

Study to Assess Safety, Efficacy, and Cellular Kinetics of YTB323 in Generalized Myasthenia Gravis

Generalized Myasthenia Gravis
Novartis Pharmaceuticals15 enrolled10 locationsNCT06704269
Recruiting
Phase 2Phase 3

KYSA-6: A Study of Anti-CD19 Chimeric Antigen Receptor T-Cell Therapy, in Patients With Generalized Myasthenia Gravis

Myasthenia GravisGeneralized Myasthenia Gravis
Kyverna Therapeutics66 enrolled14 locationsNCT06193889
Recruiting
Phase 2Phase 3

A Study of Efgartigimod PH20 SC in Children Between 2 and Less Than 18 Years of Age With Generalized Myasthenia Gravis

Generalized Myasthenia Gravis
argenx12 enrolled20 locationsNCT06392386